Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Outlook Therapeutics Inc shares valued at $28,446 were purchased by KENYON LAWRENCE A on Sep 26 ’24. At $5.69 per share, KENYON LAWRENCE A acquired 5,000 shares. The insider’s holdings grew to 5,946 shares worth approximately $8740.619999999999 following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Haddadin Yezan Munther purchased 1,882 shares, netting a total of over 22,242 in proceeds. Following the buying of shares at $11.82 each, the insider now holds 5,049 shares.
Before that, Evanson Jeff had added 62,484 shares to its account. In a trade valued at $26,243, the CHIEF COMMERCIAL OFFICER bought Outlook Therapeutics Inc shares for $0.42 each. Upon closing the transaction, the insider’s holdings increased to 62,484 shares, worth approximately $1.19 million.
As published in a research note from Chardan Capital Markets on December 02, 2024, Outlook Therapeutics Inc [OTLK] has been rated down from a Buy to a Neutral. Analysts at BTIG Research upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in late March. As of February 15, 2024, Chardan Capital Markets has increased its “Neutral” rating to a “Buy” for OTLK. Earlier on January 25, 2024, Guggenheim upgraded its rating. Their new recommendation was “a Buy” for OTLK stock which previously was a “a Neutral”.
Analyzing OTLK Stock Performance
During the last five days, there has been a drop of approximately -2.78%. Over the course of the year, Outlook Therapeutics Inc shares have dropped approximately -82.23%. Shares of the company reached a 52-week high of $12.8499 on 04/01/24 and a 52-week low of $0.8700 on 11/27/24. A 50-day SMA is recorded $4.0886, while a 200-day SMA reached $6.6679. Nevertheless, trading volume fell to 0.52 million shares from 0.79 million shares the previous day.
Support And Resistance Levels for Outlook Therapeutics Inc (OTLK)
According to the 24-hour chart, there is a support level at 1.3771, which, if violated, would cause prices to drop to 1.2843. In the upper region, resistance lies at 1.5464. The next price resistance is at 1.6229. RSI (Relative Strength Index) is 20.85 on the 14-day chart, showing oversold technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.0481, which suggests the price will decrease in the coming days. Percent R is at 66.10%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
